Page 57 - Zai Lab News Today

Dutch biotech argenx SE (ARGX) announced on Thursday that its lead product, Vyvgart (efgartigimod alfa-fcab), met the main goal in a Phase 3 trial for adults with primary...

Alberta’s government is investing in the province’s first public sector artificial intelligence (AI) lab.

The JV marks the latest move made by DNE Group to enhance its life science ecosystem.

28.04.2022 - 91% confirmed objective response rate (cORR) (10/11) in China subpopulation by Blinded Independent Central Review (BICR) in TKI-naïve cohort (EXP-1) In the TKI-naïve China subpopulation by BICR, the duration of response (DOR) range was 3.6+-7.5+ ... Seite 1

Quarterly net revenues of $137.5 million with 80% gross margin Entering a transformational period with multiple clinical catalysts expected in near-term Novocure (NASDAQ: NVCR) today reported financial

PureTech Announces Annual Results for Year Ended December 31, 2021 - read this article along with other careers information, tips and advice on BioSpace

Concerns raised about conflict of interest as Palantir bids for £240M NHS contract.

Average three-month returns from Chinese equity funds and ARK funds have plunged, as China's economy faces domestic and international pressures while small technology companies record lower profits.

Zai Lab (NASDAQ:ZLAB – Get Rating) had its target price lowered by research analysts at SVB Leerink from $102.00 to $101.00 in a report issued on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the stock. SVB Leerink’s price objective indicates a potential upside of 135.54% from the stock’s current price. Other […]

Equities Research Analysts’ price target changes for Thursday, April 21st: Alcoa (NYSE:AA) had its target price reduced by B. Riley from $91.00 to $84.00. The firm currently has a neutral rating on the stock. Alcoa (NYSE:AA) had its target price lowered by BMO Capital Markets from $99.00 to $95.00. ABB (VTX:ABBN) was given a CHF […]